HC Wainwright Has Negative Estimate for ARWR FY2026 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Analysts at HC Wainwright lowered their FY2026 EPS estimates for Arrowhead Pharmaceuticals in a report released on Thursday, August 6th. HC Wainwright analyst P. Trucchio now expects that the biotechnology company will post earnings of ($3.33) per share for the year, down from their previous estimate of ($2.68). HC Wainwright has a “Buy” rating and a $120.00 price objective on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.51) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ Q4 2026 earnings at ($2.74) EPS, Q1 2027 earnings at ($1.42) EPS, Q2 2027 earnings at ($1.64) EPS, Q3 2027 earnings at ($1.65) EPS, Q4 2027 earnings at $0.08 EPS, FY2027 earnings at ($4.61) EPS, FY2028 earnings at ($4.14) EPS, FY2029 earnings at ($1.37) EPS and FY2030 earnings at $5.42 EPS.

Several other equities research analysts also recently commented on the company. Stifel Nicolaus assumed coverage on Arrowhead Pharmaceuticals in a report on Tuesday, July 14th. They set a “buy” rating and a $98.00 target price for the company. Piper Sandler reissued an “overweight” rating and issued a $126.00 price target (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. B. Riley Financial boosted their price objective on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Sanford C. Bernstein upped their price objective on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Finally, Royal Bank Of Canada raised their target price on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $97.33.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ ARWR opened at $89.24 on Monday. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. The stock has a market capitalization of $12.57 billion, a price-to-earnings ratio of -39.66 and a beta of 1.27. The stock’s fifty day simple moving average is $80.60 and its 200 day simple moving average is $71.80. Arrowhead Pharmaceuticals has a 52-week low of $17.22 and a 52-week high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The company had revenue of $75.25 million for the quarter, compared to analyst estimates of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. Arrowhead Pharmaceuticals’s revenue was up 171.0% on a year-over-year basis. During the same quarter last year, the company posted ($1.26) EPS.

Institutional Trading of Arrowhead Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the business. M&T Bank Corp boosted its position in Arrowhead Pharmaceuticals by 2,569.6% during the fourth quarter. M&T Bank Corp now owns 240,634 shares of the biotechnology company’s stock valued at $15,976,000 after purchasing an additional 231,620 shares during the last quarter. Assenagon Asset Management S.A. increased its position in Arrowhead Pharmaceuticals by 243.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 201,927 shares of the biotechnology company’s stock worth $16,459,000 after purchasing an additional 143,192 shares during the last quarter. Kornitzer Capital Management Inc. KS acquired a new position in Arrowhead Pharmaceuticals in the 4th quarter worth about $2,375,000. Siren L.L.C. increased its position in Arrowhead Pharmaceuticals by 7.7% in the 1st quarter. Siren L.L.C. now owns 1,615,476 shares of the biotechnology company’s stock worth $101,290,000 after purchasing an additional 115,000 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft purchased a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth about $912,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.